Compare Stocks: MURA, RFAI, NMRA, and UNCY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MURA Mural Oncology	$2.04	$2.05	$1.53 ▼ $2.98	$35.38M	2.93	227,153 shs	N/A
NMRA Neumora Therapeutics	$0.50 -9.1%	$1.27	$0.48 ▼ $3.65	$93.93M	2.95	1.85 million shs	2.69 million shs
RFAI RF Acquisition Corp II	$37.92 -0.1%	$28.98	$8.94 ▼ $73.00	$133.32M	1.3	15,377 shs	2,265 shs
UNCY Unicycive Therapeutics	$4.22 -7.3%	$5.09	$3.93 ▼ $8.74	$126.74M	1.83	870,236 shs	1.50 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MURA Mural Oncology	0.00%	0.00%	0.00%	0.00%	-1.45%
NMRA Neumora Therapeutics	-9.11%	-26.22%	-63.78%	-70.07%	-71.92%
RFAI RF Acquisition Corp II	+3.02%	+22.73%	-11.82%	+243.29%	+255.68%
UNCY Unicycive Therapeutics	-7.25%	-10.21%	-18.69%	-26.35%	-5.17%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MURA Mural Oncology	$2.04	$2.05	$1.53 ▼ $2.98	$35.38M	2.93	227,153 shs	N/A
NMRA Neumora Therapeutics	$0.50 -9.1%	$1.27	$0.48 ▼ $3.65	$93.93M	2.95	1.85 million shs	2.69 million shs
RFAI RF Acquisition Corp II	$37.92 -0.1%	$28.98	$8.94 ▼ $73.00	$133.32M	1.3	15,377 shs	2,265 shs
UNCY Unicycive Therapeutics	$4.22 -7.3%	$5.09	$3.93 ▼ $8.74	$126.74M	1.83	870,236 shs	1.50 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MURA Mural Oncology	0.00%	0.00%	0.00%	0.00%	-1.45%
NMRA Neumora Therapeutics	-9.11%	-26.22%	-63.78%	-70.07%	-71.92%
RFAI RF Acquisition Corp II	+3.02%	+22.73%	-11.82%	+243.29%	+255.68%
UNCY Unicycive Therapeutics	-7.25%	-10.21%	-18.69%	-26.35%	-5.17%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MURA Mural Oncology	1.00	Sell	N/A	N/A
NMRA Neumora Therapeutics	2.78	Moderate Buy	$6.57	1,214.55% Upside
RFAI RF Acquisition Corp II	1.00	Sell	N/A	N/A
UNCY Unicycive Therapeutics	2.57	Moderate Buy	$18.25	332.46% Upside

Current Analyst Ratings Breakdown

Latest MURA, RFAI, NMRA, and UNCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/29/2026	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$15.00 ➝ $13.00
9/25/2026	NMRA Neumora Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/4/2026	RFAI RF Acquisition Corp II	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
9/4/2026	UNCY Unicycive Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/21/2026	RFAI RF Acquisition Corp II	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D)
8/20/2026	UNCY Unicycive Therapeutics	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Speculative Buy	$13.00 ➝ $15.00
8/19/2026	UNCY Unicycive Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/14/2026	NMRA Neumora Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	UNCY Unicycive Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$37.00 ➝ $25.00
8/12/2026	UNCY Unicycive Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$22.00 ➝ $20.00
8/7/2026	RFAI RF Acquisition Corp II	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)

(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MURA Mural Oncology	N/A	N/A	N/A	N/A	$8.22 per share	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$0.62 per share	N/A
RFAI RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	$680K	172.83	N/A	N/A	$1.41 per share	2.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MURA Mural Oncology	-$128.51M	-$6.93	N/A	N/A	N/A	N/A	-112.17%	-89.37%	N/A
NMRA Neumora Therapeutics	-$236.93M	-$1.23	N/A	N/A	N/A	N/A	-242.28%	-131.32%	11/5/2026 (Estimated)
RFAI RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	-$26.56M	-$1.75	N/A	1.92	N/A	N/A	-91.50%	-61.47%	11/11/2026 (Estimated)

Latest MURA, RFAI, NMRA, and UNCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	NMRA Neumora Therapeutics	-$0.2401	-$0.23	+$0.0101	-$0.23	N/A	N/A
8/12/2026	Q2 2026	UNCY Unicycive Therapeutics	-$0.4710	-$0.06	+$0.4110	-$0.06	$22.22 million	N/A
8/7/2026	Q2 2026	RFAI RF Acquisition Corp II	N/A	$0.01	N/A	$0.01	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MURA Mural Oncology	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A
RFAI RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MURA Mural Oncology	N/A	5.90	5.90
NMRA Neumora Therapeutics	1.19	4.50	4.50
RFAI RF Acquisition Corp II	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	3.81	3.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MURA Mural Oncology	80.21%
NMRA Neumora Therapeutics	47.65%
RFAI RF Acquisition Corp II	N/A
UNCY Unicycive Therapeutics	40.42%

Insider Ownership

Company	Insider Ownership
MURA Mural Oncology	2.20%
NMRA Neumora Therapeutics	26.94%
RFAI RF Acquisition Corp II	39.10%
UNCY Unicycive Therapeutics	6.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MURA Mural Oncology	119	17.34 million	16.96 million	Optionable
NMRA Neumora Therapeutics	63	187.90 million	137.28 million	Optionable
RFAI RF Acquisition Corp II	2	3.51 million	2.14 million	N/A
UNCY Unicycive Therapeutics	22	27.85 million	26.18 million	Not Optionable

MURA, RFAI, NMRA, and UNCY Headlines

Recent News About These Companies

UNCY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

3 hours ago | newsfilecorp.comN

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

October 2 at 7:34 PM | globenewswire.com

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

October 2 at 6:17 PM | newsfilecorp.comN

Kaplan Fox Class Action Reminder: Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Lead Plaintiff Deadline is November 2, 2026

October 2 at 5:26 PM | newmediawire.comN

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Receives Average Rating of "Moderate Buy" from Analysts

October 2 at 4:29 AM | americanbankingnews.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Stock Rated "Moderate Buy" by Wall Street Analysts

October 2 at 4:28 AM | marketbeat.com

Kaplan Fox Reminds Unicycive Therapeutics, Inc. (UNCY) Investors to Seek a Leadership Role Before Deadline on November 2, 2026

October 1 at 6:25 PM | newsfilecorp.comN

DEADLINE ALERT for HYLN, HIMS, UNCY, BIDU: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

October 1 at 4:00 PM | globenewswire.com

UNCY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

October 1 at 1:18 PM | newsfilecorp.comN

Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

October 1 at 12:00 PM | globenewswire.com

UNCY Shareholder Alert: Unicycive Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt

October 1 at 10:11 AM | prnewswire.com

Unicycive Therapeutics Appoints Meredith Manning to Board of Directors

October 1 at 7:05 AM | globenewswire.com

HC Wainwright Issues Optimistic Outlook for UNCY Earnings

October 1 at 6:12 AM | americanbankingnews.com

HC Wainwright Issues Optimistic Forecast for UNCY Earnings

October 1 at 6:11 AM | marketbeat.com

Unicycive Therapeutics (NASDAQ:UNCY) Stock Price Target Cut by HC Wainwright

October 1 at 1:24 AM | americanbankingnews.com

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

September 30 at 7:12 PM | newsfilecorp.comN

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 2, 2026 in Unicycive Therapeutics, Inc. Lawsuit - UNCY

September 30 at 12:53 PM | prnewswire.com

Robbins LLP Urges UNCY Stockholders with Significant Losses to Contact the Firm for Information About the Unicycive Therapeutics, Inc. Class Action

September 30 at 2:20 AM | prnewswire.com

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

September 29, 2026 | newsfilecorp.comN

Kaplan Fox Notifies Investors of Unicycive Therapeutics, Inc. (UNCY) of the Lead Plaintiff Deadline on November 2, 2026

September 29, 2026 | newsfilecorp.comN

UNCY LAWSUIT: Unicycive Therapeutics Investors Should Contact Block & Leviton to Possibly Recover Losses

September 29, 2026 | newsfilecorp.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

MURA, RFAI, NMRA, and UNCY Company Descriptions

Mural Oncology NASDAQ:MURA

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.

Neumora Therapeutics NASDAQ:NMRA

$0.50 -0.05 (-9.11%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$0.50 0.00 (-0.38%)

As of 10/2/2026 07:59 PM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

RF Acquisition Corp II NASDAQ:RFAI

$37.92 -0.04 (-0.12%)

Closing price 10/2/2026 03:57 PM Eastern

Extended Trading

$36.96 -0.96 (-2.53%)

As of 10/2/2026 07:50 PM Eastern

RF Acquisition Corp. II operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 5, 2024, and is headquartered in Singapore.

Unicycive Therapeutics NASDAQ:UNCY

$4.22 -0.33 (-7.25%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$4.24 +0.02 (+0.55%)

As of 10/2/2026 07:56 PM Eastern

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MURA, RFAI, NMRA, and UNCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MURA, RFAI, NMRA, and UNCY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MURA, RFAI, NMRA, and UNCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MURA, RFAI, NMRA, and UNCY Company Descriptions

Mural Oncology NASDAQ:MURA

Neumora Therapeutics NASDAQ:NMRA

RF Acquisition Corp II NASDAQ:RFAI

Unicycive Therapeutics NASDAQ:UNCY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MURA, RFAI, NMRA, and UNCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MURA, RFAI, NMRA, and UNCY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MURA, RFAI, NMRA, and UNCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MURA, RFAI, NMRA, and UNCY Company Descriptions

Mural Oncology NASDAQ:MURA

Neumora Therapeutics NASDAQ:NMRA

RF Acquisition Corp II NASDAQ:RFAI

Unicycive Therapeutics NASDAQ:UNCY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools